Abstract
Background
There is limited data from India with regard to presentation, practice patterns and survivals in resected pancreatic ductal adenocarcinomas (PDACs).
Methods
The Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP) included data from 8 major academic institutions across India and presents the outcomes in upfront resected PDACs from January 2015 to June 2019.
Results
Of 288 patients, R0 resection was achieved in 81% and adjuvant therapy was administered in 75% of patients. With a median follow-up of 42 months (95% CI: 39–45), median DFS for the entire cohort was 39 months (95% CI: 25.4–52.5), and median overall survival (OS) was 45 months (95% CI: 32.3–57.7). A separate analysis was done in which patients were divided into 3 groups: (a) those with stage I and absent PNI (SI&PNI-), (b) those with either stage II/III OR presence of PNI (SII/III/PNI+), and (c) those with stage II/III AND presence of PNI (SII/III&PNI+). The DFS was significantly lesser in patients with SII/III&PNI+ (median 25, 95% CI: 14.1–35.9 months), compared to SII/III/PNI + (median 40, 95% CI: 24–55 months) and SI&PNI- (median, not reached) (p = 0.036)).
Conclusions
The MIPPAP study shows that resectable PDACs in India have survivals at par with previously published data. Adjuvant therapy was administered in 75% patients. Adjuvant radiotherapy does not seem to add to survival after R0 resection.
Similar content being viewed by others
Availability of Data and Materials
Available on the reasonable requests through proper channels.
References
Gaidhani RH, Balasubramaniam G. An epidemiological review of pancreatic cancer with special reference to India. Indian J Med Sci. 2021;73(1):99–109.
Conroy T, Ducreux M. Adjuvant treatment of pancreatic cancer. Curr Opin Oncol. 2019;31(4):346–53.
Boyle J, Czito B, Willett C, Palta M. Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. J Gastrointest Oncol. 2015;6(4):436–44.
Gamboa AC, Lee RM, Maithel SK. The role of radiation for pancreatic adenocarcinoma. J Pancreatol. 2020;3(2):72–80.
Roalsø M, Aunan JR, Søreide K. Refined TNM-staging for pancreatic adenocarcinoma – real progress or much ado about nothing? Eur J Surg Oncol. 2020;46(8):1554–7.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71(3):209–49.
Zhang JF, Hua R, Sun YW, Liu W, Huo YM, Liu DJ, et al. Influence of perineural invasion on survival and recurrence in patients with resected pancreatic cancer. Asian Pac J Cancer Prev. 2013;14(9):5133–9.
Crippa S, Pergolini I, Javed AA, Honselmann KC, Weiss MJ, Di Salvo F, et al. Implications of perineural invasion on disease recurrence and survival after pancreatectomy for pancreatic head ductal adenocarcinoma. Annals of Surgery [Internet]. 2022 [cited 2022 Mar 28]; Available from https://journals.lww.com/annalsofsurgery/abstract/9000/implications_of_perineural_invasion_on_disease.94091.aspx.
Hong SB, Lee SS, Kim JH, Kim HJ, Byun JH, Hong SM, et al. Pancreatic cancer CT: prediction of resectability according to NCCN criteria. Radiology. 2018;289(3):710–8.
Van Eijck CHJ, Versteijne E, Suker M, Groothuis K, Besselink MGH, Busch ORC, et al. Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: long-term results of the multicenter randomized phase III PREOPANC trial. JCO. 2021;39(15_suppl):4016–4016.
Chaudhari VA, Mitra A, Gupta V, Ostwal V, Ramaswamy A, Engineer R, et al. Neoadjuvant therapy in borderline resectable pancreatic cancer: outcomes in the era of changing practices and evolving evidence. Surgery. 2022;171(5):1388–95.
Verbeke CS. Resection margins and R1 rates in pancreatic cancer – are we there yet? Histopathology. 2008;52(7):787–96.
Fatima J, Schnelldorfer T, Barton J, Wood CM, Wiste HJ, Smyrk TC, et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 2010;145(2):167–72.
Kim KS, Kwon J, Kim K, Chie EK. Impact of resection margin distance on survival of pancreatic cancer: a systematic review and meta-analysis. Cancer Res Treat. 2016;49(3):824–33.
Pasqualetti F, Sainato A, Morganti R, Laliscia C, Vasile E, Gonnelli A, et al. Adjuvant radiotherapy in patients with pancreatic adenocarcinoma. Is it still appealing in clinical trials? A meta-analysis and review of the literature. Anticancer Res. 2021;41(10):4697–704.
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.
Kagedan DJ, Ahmed M, Devitt KS, Wei AC. Enhanced recovery after pancreatic surgery: a systematic review of the evidence. HPB (Oxford). 2015;17(1):11–6.
Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10(1):16425.
Author information
Authors and Affiliations
Contributions
All authors contributed equally to the manuscript. Concept and data analysis: VO, AR, VC.
Corresponding author
Ethics declarations
Competing Interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chaudhari, V., Ramaswamy, A., Srinivas, S. et al. Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) — Results from the Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP) Study. J Gastrointest Canc 54, 1338–1346 (2023). https://doi.org/10.1007/s12029-023-00936-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-023-00936-1